{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T09:32:32Z","timestamp":1793179952222,"version":"4.5.0"},"reference-count":41,"publisher":"European Respiratory Society (ERS)","issue":"176","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2025,1,28]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>\n                    Asthma treatment has seen significant advancements over the recent years. However, despite improvements in disease control, some patients continue to experience persistent symptoms and exacerbations, necessitating a deeper understanding of disease mechanisms and optimisation of treatment strategies. The introduction of biologics has marked a new era in severe asthma management, targeting underlying molecular mechanisms and raising the possibility of achieving asthma remission. Key indicators of remission include high asthma control, absence of exacerbations and stabilised, or normalised, lung function. However, there is currently no common definition for remission, with various studies using different criteria. Real-world studies and\n                    <jats:italic>post hoc<\/jats:italic>\n                    analyses of clinical trials emphasise the potential of biologics in achieving clinical remission in a significant proportion of patients. Here, we provide a comprehensive review of studies in support of incorporating asthma remission as potential goal in asthma management. Despite the lack of a universally accepted definition and large prospective studies focused on remission, we believe that incorporating long-term outcomes and the currently accepted elements of remission in the approach to asthma care will shift the emphasis from reactive symptom control to proactive disease management, ultimately aiming for better asthma outcomes.\n                  <\/jats:p>","DOI":"10.1183\/16000617.0181-2024","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T06:48:27Z","timestamp":1743576507000},"page":"240181","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Pro: Clinical remission in asthma \u2013 implications for asthma management"],"prefix":"10.1183","volume":"34","author":[{"given":"Stefania","family":"Principe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar N.","family":"Jarjour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"2025063008350742000_34.176.240181.1","unstructured":"Global Initiative for Asthma . Global Initiative for Asthma. Date last accessed: 3 March 2022. Date last updated: 2025. https:\/\/ginasthma.org\/"},{"key":"2025063008350742000_34.176.240181.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02125-0"},{"key":"2025063008350742000_34.176.240181.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01724.x"},{"key":"2025063008350742000_34.176.240181.4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02583-2021"},{"key":"2025063008350742000_34.176.240181.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.12.006"},{"key":"2025063008350742000_34.176.240181.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2011.01.002"},{"key":"2025063008350742000_34.176.240181.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.09.033"},{"key":"2025063008350742000_34.176.240181.8","doi-asserted-by":"crossref","first-page":"2100396","DOI":"10.1183\/13993003.00396-2021","article-title":"Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)","volume":"59","author":"Moore","year":"2021","journal-title":"Eur Respir J"},{"key":"2025063008350742000_34.176.240181.9","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00415-0"},{"key":"2025063008350742000_34.176.240181.10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01844-2023"},{"key":"2025063008350742000_34.176.240181.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.08.609"},{"key":"2025063008350742000_34.176.240181.12","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/j.jaip.2023.07.041","article-title":"Severe Asthma Network Italy definition of clinical remission in severe asthma: a Delphi consensus","volume":"11","author":"Canonica","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025063008350742000_34.176.240181.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00331-2"},{"key":"2025063008350742000_34.176.240181.14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.arbres.2024.04.002","article-title":"Spanish consensus on remission in asthma (REMAS)","volume":"60","author":"\u00c1lvarez-Guti\u00e9rrez","year":"2024","journal-title":"Arch Bronconeumol"},{"key":"2025063008350742000_34.176.240181.15","first-page":"10","article-title":"Exploring definitions and predictors of severe asthma clinical remission post-biologic in adults","volume":"18","author":"Perez-de-Llano","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2025063008350742000_34.176.240181.16","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00819-2023"},{"key":"2025063008350742000_34.176.240181.17","doi-asserted-by":"crossref","first-page":"1150162","DOI":"10.3389\/fimmu.2023.1150162","article-title":"Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study","volume":"14","author":"Pavord","year":"2023","journal-title":"Front Immunol"},{"key":"2025063008350742000_34.176.240181.18","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.3390\/ijms24032455","article-title":"Severe asthma remissions induced by biologics targeting IL5\/IL5r: results from a multicenter real-life study","volume":"24","author":"Maglio","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025063008350742000_34.176.240181.19","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.3390\/jcm13103013","article-title":"Unlocking the long-term effectiveness of benralizumab in severe eosinophilic asthma: a three-year real-life study","volume":"13","author":"Pini","year":"2024","journal-title":"J Clin Med"},{"key":"2025063008350742000_34.176.240181.20","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.jaip.2023.05.047","article-title":"Response to biologics and clinical remission in the adult German asthma net severe asthma registry cohort","volume":"11","author":"Milger","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025063008350742000_34.176.240181.21","doi-asserted-by":"publisher","DOI":"10.1111\/all.15867"},{"key":"2025063008350742000_34.176.240181.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.10.046"},{"key":"2025063008350742000_34.176.240181.23","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.3390\/jcm12082900","article-title":"A real-world study of achievement rate and predictive factors of clinical and deep remission to biologics in patients with severe asthma","volume":"12","author":"Oishi","year":"2023","journal-title":"J Clin Med"},{"key":"2025063008350742000_34.176.240181.24","doi-asserted-by":"crossref","first-page":"107348","DOI":"10.1016\/j.rmed.2023.107348","article-title":"Severe asthma clinical remission after biologic treatment with anti-IL4\/IL13: a real-life experience","volume":"217","author":"Portacci","year":"2023","journal-title":"Respir Med"},{"key":"2025063008350742000_34.176.240181.25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/jcm13010291","article-title":"Clinical remission in patients affected by severe eosinophilic asthma on dupilumab therapy: a long-term real-life study","volume":"13","author":"Quarato","year":"2024","journal-title":"J Clin Med"},{"key":"2025063008350742000_34.176.240181.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.04.028"},{"key":"2025063008350742000_34.176.240181.27","doi-asserted-by":"crossref","first-page":"AB4","DOI":"10.1016\/j.jaci.2020.12.061","article-title":"Dupilumab treatment leads to clinical asthma remission in patients with uncontrolled moderate-to-severe asthma with type 2 inflammation","volume":"147","author":"Pavord","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2025063008350742000_34.176.240181.28","first-page":"A5995","article-title":"Dupilumab induces clinical remission in patients with uncontrolled, moderate-to-severe, type 2 inflammatory asthma","volume":"207","author":"Pavord","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025063008350742000_34.176.240181.29","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02098-1"},{"key":"2025063008350742000_34.176.240181.30","first-page":"A4756","article-title":"Clinical remission and associated reductions in background medication in patients with severe asthma: an analysis of the phase 3b ANDHI in practice substudy","volume":"207","author":"Harrison","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2025063008350742000_34.176.240181.31","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2023.OA1420"},{"key":"2025063008350742000_34.176.240181.32","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00316-2024"},{"key":"2025063008350742000_34.176.240181.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02284-5"},{"key":"2025063008350742000_34.176.240181.34","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201003-0494OC"},{"key":"2025063008350742000_34.176.240181.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.04.030"},{"key":"2025063008350742000_34.176.240181.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.01.037"},{"key":"2025063008350742000_34.176.240181.37","unstructured":"ClinicalTrials.gov . 3TR Asthma Biologics Cohort (ABC) Study (3TR-ABC). Date last accessed: 25 June 2024. Date last updated: 13 November 2023. https:\/\/clinicaltrials.gov\/study\/NCT06126692"},{"key":"2025063008350742000_34.176.240181.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.08.054"},{"key":"2025063008350742000_34.176.240181.39","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1016\/j.jaip.2021.02.031","article-title":"Asthma patients who stop asthma biologics have a similar risk of asthma exacerbations as those who continue asthma biologics","volume":"9","author":"Jeffery","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025063008350742000_34.176.240181.40","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00404-2024"},{"key":"2025063008350742000_34.176.240181.41","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1080\/02770903.2024.2366523","article-title":"Asthma remission one, none and one-hundred thousand: the relevance of the patient's view","volume":"61","author":"Bonini","year":"2024","journal-title":"J Asthma"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0181-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T11:35:28Z","timestamp":1751283328000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0181-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":41,"journal-issue":{"issue":"176","published-online":{"date-parts":[[2025,4,2]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1183\/16000617.0181-2024"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0181-2024","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}